|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Payment measure ($’000) | **Lead agency** | **2024** | **2025** | **2026** | **2027** | **2028** |
| **–25** | **–26** | **–27** | **–28** | **–29** |
| **Attributed to All Outcomes** | | | | | | |
| Department of Veterans' Affairs – additional resourcing to support service delivery | Veterans’ Affairs (DVA) | - | 47,626 | - | - | - |
| **Attributed to All Outcome 1 Programs** | | | | | | |
| Savings from External Labour – further extension (a) | Cross Portfolio | - | - | - | - | (4,160) |
| **2.1 General Medical Consultation and Services** | | | | | | |
| Health - savings (b) | Health and Aged Care (Health) |  | (89) | (7) | - | - |
| Pharmaceutical Benefits Scheme (PBS) New and Amended Listings (b) | Health | 26 | 73 | 93 | 94 | 89 |
| Strengthening Medicare (b) | Health | - | 687 | 1,192 | 1,152 | 1,300 |
| Strengthening Medicare - Expanding Medicare Urgent Care Clinics (b) (c) | Health | - | 67 | 5 | - | - |
| Strengthening Medicare - Health Workforce (b) (d) | Health | - | 13 | 15 | 16 | 17 |
| Strengthening Medicare - Women's Health (b) (e) | Health | - | - | - | - | - |
| **2.3 Veterans' Pharmaceuticals Benefits** | | | | | | |
| Improving Access to Medicines and Pharmacy Programs (b) (f) | Health | - | - | - | - | - |
| Pharmaceutical Benefits Scheme (PBS) New and Amended Listings (b) | Health | 1,075 | 4,757 | 6,562 | 7,885 | 8,825 |
| **2.4 Veterans' Community Care and Support** | | | | | | |
| Continuing to Support Veterans and their Families (g) | DVA | - | 4,201 | - | - | - |
| Funding Pay Increases for Aged Care Workers - nurses (b) | Health | - | 134 | 134 | - | - |
| Strengthening Medicare - Health Workforce (b) (d) | Health | - | 70 | 69 | 74 | 79 |
| **2.5 Veterans' Counselling and Other Health Services** | | | | | | |
| Continuing to Support Veterans and their Families (g) | DVA | - | 6,617 | - | - | - |
| **Total DVA funding** | | **1,101** | **64,156** | **8,063** | **9,221** | **6,150** |

1. *The full measure description and package details appear in the Budget Paper No. 2 under Cross Portfolio.*
2. *The lead entity for this measure is the Department of Health and Aged Care. The full measure description and package details appear in the Budget Paper No. 2 under the Health and Aged Care portfolio.*
3. *This measure includes a decision taken but not yet announced item in the 2024-25 MYEFO, with the following impact: 2025-26 $0.558 million; 2026-27 $0.616 million; 2027-28 $0.627 million and 2028-29 $0.045 million.*
4. *This measure includes a decision taken but not yet announced item in the 2024-25 MYEFO, with the following impact: 2025-26 -$0.120 million; 2026-27 -$0.345 million; 2027-28 -$0.400 million and 2028-29 -$0.444 million.*
5. *This measure was a decision taken but not yet announced in the 2024-25 MYEFO, with the following impact: 2025-26 $0.415 million; 2026-27 $0.626 million; 2027-28 $0.475 million and 2028-29 $0.460 million.*
6. *This measure has been announced since the 2024-25 MYEFO and was published in the 2024-25 Veterans' Affairs' Portfolio Additional Estimates Statements under First Pharmaceutical Wholesaler Agreement.*
7. *The cost of this measure will be partially met from within existing resourcing of the Department of Veterans' Affairs.*